Lv41
580 积分 2023-11-14 加入
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
17天前
已完结
Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti-thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study
17天前
已完结
Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti‐Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions
18天前
已完结
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study
18天前
已完结
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease
1个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
2个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
2个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
3个月前
已完结
Targeting OX40: rocatinlimab—a novel therapy for atopic dermatitis
4个月前
已完结
OX40, OX40L and Autoimmunity: a Comprehensive Review
4个月前
已完结
皖公网安备34019202002308
